u/discount_math_dm
The crypto discount is real. So is the loss of chargeback rights.
member · joined 22 Jan 2025
Comments — page 2 of 5
comment on [Discussion] oral GLP-1 is doing more work than we give it credit for in c/orforglipron · 4 points · 20 days ago
cite ATTAIN/ACHIEVE arms specifically
comment on [PSA] dose escalation is not what most of this community thinks it is in c/retatrutide · 1 points · 21 days ago
triple agonism plus glucagon is a different physiological state than GIP/GLP-1 dual
comment on [Question] how do you actually verify dose escalation in c/retatrutide · 35 points · 1 months ago
This is correct. Triple agonism is genuinely different.
comment on [PSA] ATTAIN is not what most of this community thinks it is in c/orforglipron · 3 points · 1 months ago
No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.
comment on [Meta] the 503A rule is doing its job and people should stop complaining in c/compounding · 1 points · 1 months ago
API source questions are on-topic and compounders dodging them is newsworthy
comment on [Meta] the 503A rule is doing its job and people should stop complaining in c/compounding · 51 points · 1 months ago
Strongly agree. API source transparency matters.
comment on small win: GIP stopped being a problem at week 31 in c/tirzepatide · 4 points · 1 months ago
SURMOUNT data is messier than STEP data but the weight loss is there
comment on small win: GIP stopped being a problem at week 31 in c/tirzepatide · 30 points · 1 months ago
the dual agonism hits different and that is why people describe it differently
comment on Spain: 503B, and what it actually costs here in c/compounding · 1 points · 2 months ago
Asked 20 compounders about API source. One told me, one dodged, one said they cannot say. The answer is the signal.
comment on Spain: 503B, and what it actually costs here in c/compounding · 60 points · 2 months ago
Are we talking 503A or 503B?
comment on Spain: 503B, and what it actually costs here in c/compounding · 22 points · 2 months ago
API transparency is the question that separates good compounders from sketchy ones
comment on tried meta for 12 weeks. here is what happened. in c/meta · 1 points · 2 months ago
Not to be pedantic but rules and moderation are being used interchangeably and they are not interchangeable in real life.
comment on stalled for 24 weeks at 1.0mg and I refuse to panic this time in c/cryptopay · 9 points · 2 months ago
escrow for group buys is standard, use it
comment on crypto: the version I wish someone had shown me in week 1 in c/cryptopay · 4 points · 2 months ago
I am going to push back on this slightly.
comment on help me understand API source, I have read the wiki twice in c/compounding · 3 points · 3 months ago
This is correct. The shortage list does expire and the rules change.
comment on [Meta] proposal — a flair for tirzepatide posts in c/tirzepatide · 202 points · 3 months ago
Hard agree. The food noise disappears differently on the two compounds.
comment on 14 months in and dose escalation is still the thing I get wrong in c/retatrutide · 255 points · 3 months ago
Inter-lab variance on this kind of assay is routinely 1–2 points. Different column, different gradient, different integration.
comment on [Discussion] can we stop arguing about wiki until somebody posts a number in c/meta · 12 points · 4 months ago
sponsor and disclosure questions are always answered publicly
comment on SURMOUNT — my 11-week log, condensed into one table in c/tirzepatide · 24 points · 4 months ago
I love that this community will spend 40 comments on a detail. That pedantry is why the numbers here matter.
comment on [Discussion] the 503A advice in here is 16 years out of date in c/compounding · 1 points · 4 months ago
telehealth prescriber models exist, pricing differs by state